Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing novel therapies for patients with bleeding and thrombotic disorders. The company focuses on coagulation disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding. Its pipeline includes sutacimig, a subcutaneously administered bispecific antibody for Glanzmann thrombasthenia; HMB-002, a monovalent antibody designed to accumulate endogenous von Willebrand Factor for Von Willebrand Disease; and HMB-003, a peptide-based plasmin inhibitor for heavy menstrual bleeding. Hemab utilizes a modality-agnostic approach to stabilize coagulation proteins and direct them to injury sites. The company conducts natural history studies and clinical trials to address unmet medical needs in these conditions.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage ir.hemab.com
Sector Healthcare IR page ir.hemab.com
Tags
hematology, coagulation disorders, bispecific antibodies, monoclonal antibodies, peptide therapeutics, glanzmann thrombasthenia, von willebrand disease, heavy menstrual bleeding, prophylactic therapy, sutacimig, HMB-002, HMB-003, VWD 360, VELORA Discover, VELORA Pioneer
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026 Q1 2026
Assets 442.712M 467.781M 175.258M
Net profit -27.304M -24.15M -22.687M
Free cash flow -28.325M -22.66M -21.696M

Figure Q3 2026 Q2 2026 Q1 2026
Share price 30.84 36.73 —
P/FCF -12.72 -18.93 —

Filed figures

Figure Dec 2025
Balance sheet detail
Lease liabilities (USD) 1.22M
Cash and deposits (USD) 88M
Right-of-use assets (USD) 1.09M
Reported May 21, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding,

a condition affecting more than 23 million women in the U.S. alone

Announced data showing HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model;

data to be presented at the 68th ASH Annual Meeting and Exposition in December 2026

Announced first clinical data for sutacimig in Factor VII deficiency (FVIID), showing shortening of

prothrombin time by more than 50% in both participants and ~5x accumulation of endogenous FVII(a) in

the participant with PK/PD data, after a single dose; updated Phase 2b data to be presented at ASH in

December 2026

Initiated SOLARA, a pivotal Phase 3 trial of once-weekly subcutaneous sutacimig in Glanzmann

thrombasthenia (GT), the first pivotal trial of a subcutaneous prophylactic treatment in GT

Expects to present data from the ongoing VELORA Pioneer Phase 1/2 trial of HMB-002 in Von Willebrand

Disease at the 20th EAHAD (European Association for Haemophilia and Allied Disorders) Congress in

February 2027

Strengthened Board of Directors with the appointment of Keli Walbert bringing two decades of

commercial leadership and p

On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Hemab Therapeutics Holdings, Inc. (the “Company”), the Board elected Keli Walbert to serve as a member of the Board, effective immediately. Ms. Walbert will serve as a Class I director with a term expiring at the 2027 annual meeting of stockholders and thereafter until her successor has been duly elected and qualified or until her earlier death, resignation or removal. The Board also elected Ms. Walbert to serve as a member of the Audit Committee of the Board (the “Audit Committee”). There are no arrangements or understandings between Ms. Walbert and any other persons pursuant to which she was elected as a director. Ms. Walbert has no family relationships with any of the Company’s directors or executive officers. There are no transactions and no proposed transactions between Ms. Walbert and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K. Ms.

September 24, 2026

Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the appointment of Keli Walbert to its Board of Directors, effective September 24, 2026. Ms. Walbert will join the Board’s Audit Committee, succeeding Akshay Vaishnaw, MD, PhD, who will remain a member of the Board.

“Keli's experience turning novel scientific innovations into therapies that reach patients is exactly what Hemab needs as we work to close longstanding gaps in the treatment of bleeding disorders,” said Benny Sørensen, MD, PhD, CEO of Hemab. “As we advance our pipeline toward later-stage development, her experience building the commercial capabilities that bring new therapies to people with high-unmet-need conditions will strengthen our Board at a pivotal time for Hemab.”

“We are pleased to welcome Keli to Hemab's Board of Directors. Her commercial expertise strengthens our Board as we work to bring new therapies to people living with serious, underserved bleeding disorders,” said John Maraganore, PhD, Chair of Hemab's Board of Directors. “Her success launching medicines from very common to rare diseases is a good strategic match as we advance toward key milestones across the pipeline.”

Ms. Walbert brings more than 20 years of commercial leadership experience in biopharmaceuticals, spanning sales and marketing, market access, patient services, advocacy, and analytics. Her therapeutic background covers immunology, rheumatology, dermatology, gastroenterology, ophthalmology, nephrology, neurology and metabolic disease, with experience in indications of all market sizes. She most recently served as Executive Vice President, U.S. Commercial at Horizon Therapeutics, where she oversaw commercial strategy and organizational development across more than 10 marketed brands. Earlier in her career, she held leadership roles at AbbVie, the American Medical Association, Abbott and United Healthcare. Over the course of her career, she led the commercial launches of HUMIRA®, TEPEZZA® and DUOPA®. She has been recognized with the Healthcare Businesswomen's Association's Luminary Award and an MM+M Women of Distinction Award. She earned her master's degree from Northwestern University and bachelor's degree from the University of Louisville.

“I'm honored to join Hemab's Board at such a pivotal moment for the company,” said Ms. Walbert. “Hemab's mission to bring new options to people living with serious, high-unmet-need bleeding disorders reflects the kind of impact I've built my career around, and I look forward to helping them move their pipeline to patients as quickly and effectively as possible.”

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Prompts

Hemab Therapeutics Holdings, Inc. (ticker COAG), listed in United States.

ETFs Holding Hemab Therapeutics Holdings, Inc.

ETF Weight in ETF Shares Market value As of
FFSM 0.10% 32,749 $ 1.557M Jul 31, 2026
TMSL 0.04% 32,484 $ 1.193M Jun 30, 2026
MSSM 0.02% 2,457 $ 112.359K Aug 31, 2026
FBCG 0.00% 4,678 $ 222.439K Jul 31, 2026
AVUS 0.00% 625 $ 24.409K Nov 16, 2026
AVUQ 0.00% 387 $ 15.114K Nov 16, 2026